KLRS
Kalaris Therapeutics, Inc.
$4.09
-2.04%
$99.2M
No data for this timeframe.
Vol
Market Cap$99.2M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders6 funds
Inst. Value$3.8M
Inst. Activity3 buys / 0 sells
Insider Activity2B / 1S
Insider Net $$6.2M
Reddit Sentiment58° Warm
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001754068·Prev Close $4.17
Recent Activity
Jun 3, 2026
Insider
PATTERSON LEONE D sold 9,000 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
ADAMIS ANTHONY P sold 9,000 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
Dybbs Michael sold 9,000 shares
Director @ $0.00 ($0.00)
May 20, 2026
earnings_calendar
KLRS Q1 2026 Earnings Scheduled — 2026-05-20
May 12, 2026
SEC
Kalaris Therapeutics reported Q1 2026 financial results, with net loss widening to $10.9M from $10.2M YoY and cash decre
8-K — Impact 4/10
May 12, 2026
SEC
Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by 11.5%. The company
PRESS-RELEASE — Impact 4/10
Apr 24, 2026
SEC
Kalaris Therapeutics is holding its 2026 annual meeting to vote on the election of three Class III directors, approval o
DEFA14A — Impact 3/10
Inst.
VANGUARD GROUP INC — ADD
292,790 shares ($2.5M)
Price Targets
$18.75
+359.0% upside
Strong Buy
Current $4.09
Low $7.00
Median $19.50
High $25.00
8 analysts
$7.00
$25.00
Analyst Ratings
6Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Wedbush | INITIATE | Outperform |
| May 13, 2026 | Citizens | MAINTAIN | Market Outperform → Market Outperform |
| Apr 16, 2026 | Morgan Stanley | INITIATE | Overweight |
| Dec 23, 2025 | Chardan Capital | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.50 ▲ +8.8% | $-0.55 — $-0.38 | 18% YoY | 7 |
| Next Q | $-0.53 ▲ +7.8% | $-0.58 — $-0.39 | 18% YoY | 7 |
| Current FY | $-2.05 ▲ +9.0% | $-2.19 — $-1.62 | 28% YoY | 7 |
| Next FY | $-1.58 ▼ -8.6% | $-2.21 — $0.65 | 23% YoY | 8 |
Latest Reports
NEUTRAL
8-K
4/10
Kalaris Therapeutics reported Q1 2026 financial results, with net loss widening to $10.9M from $10.2M YoY and cash decre
May 12, 2026
NEUTRAL
PRESS-RELEASE
4/10
Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by 11.5%. The company
May 12, 2026
BULLISH
Press
7/10
Kalaris Therapeutics reported financial results for 2025, highlighted by positive Phase 1a data for its nAMD candidate T
Mar 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $2.5M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $740.6K | DOUBLED |
| MORGAN STANLEY | $235.9K | DOUBLED |
| TWO SIGMA INVESTMENTS, LP | $234.3K | NEW |
| FMR LLC | $65.9K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | PATTERSON LEONE | A | $0.00 |
| Jun 3, 2026 | ADAMIS ANTHONY | A | $0.00 |
| Jun 3, 2026 | Dybbs Michael | A | $0.00 |
| Jun 3, 2026 | AKKARAJU SRINIVAS | A | $0.00 |
| Jun 3, 2026 | Hallal David | A | $0.00 |
Reddit Sentiment
58°
Warm
Bearish
Neutral
Bullish
6 institutional holders with $3.8M total value (450,758 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net buying activity: 3 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 292,790 | $2.5M | 65.0% | ADD +44.2% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 87,751 | $740.6K | 19.5% | DOUBLED +402.6% |
| 3 | MORGAN STANLEY | 27,948 | $235.9K | 6.2% | DOUBLED +1168.7% |
| 4 | TWO SIGMA INVESTMENTS, LP | 27,759 | $234.3K | 6.2% | NEW |
| 5 | FMR LLC | 7,806 | $65.9K | 1.7% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 6,704 | $56.6K | 1.5% | DOUBLED +2989.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 203,051 | 292,790 | +44.2% | $2.5M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 27,759 | — | $234.3K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 217 | 6,704 | +2989.4% | $56.6K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 129,839 | 203,051 | +56.4% | $1.2M | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 1,964 | 24,918 | +1168.7% | $144.0K | 2025-Q3 |
| UBS Group AG | ADD | 4,116 | 5,252 | +27.6% | $30.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 19,251 | 96,751 | +402.6% | $258.3K | 2025-Q2 |
| UBS Group AG | TRIM | 9,261 | 4,116 | -55.6% | $11.0K | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,296 | 1,964 | +51.5% | $5.2K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 5,424 | 273 | -95.0% | $729.00 | 2025-Q2 |
| VANGUARD GROUP INC | NEW | — | 115,086 | — | $924.1K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 19,251 | — | $154.6K | 2025-Q1 |
| UBS Group AG | NEW | — | 9,261 | — | $74.4K | 2025-Q1 |
| FMR LLC | NEW | — | 7,806 | — | $62.7K | 2025-Q1 |
| MORGAN STANLEY | NEW | — | 1,296 | — | $10.4K | 2025-Q1 |
11 unique insiders with 3 transactions. Net insider value: $6.2M ($6.2M bought, $12.9K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | PATTERSON LEONE D | Director | A | 9,000 | $0.00 | $0.00 |
| Jun 3, 2026 | ADAMIS ANTHONY P | Director | A | 9,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Dybbs Michael | Director | A | 9,000 | $0.00 | $0.00 |
| Jun 3, 2026 | AKKARAJU SRINIVAS | Director | A | 9,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Hallal David | Director | A | 9,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Ferrara Napoleone | Director | A | 9,000 | $0.00 | $0.00 |
| Jun 3, 2026 | Jovan-Embiricos Morana | Director | A | 9,000 | $0.00 | $0.00 |
| May 20, 2026 | AKKARAJU SRINIVAS | Director | BUY | 244,300 | $4.83 | $1.2M |
| May 20, 2026 | AKKARAJU SRINIVAS | Director | J | 66,906 | $0.00 | $0.00 |
| Mar 20, 2026 | Hagen Brett R | Chief Accounting Officer | SELL | 1,915 | $6.72 | $12.9K |
| Mar 19, 2026 | Gall Matthew | Chief Financial Officer | A | 95,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Feinsod Matthew | Chief Medical Officer | A | 135,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Oxtoby Andrew | See Remarks | A | 222,000 | $0.00 | $0.00 |
| Mar 19, 2026 | Hagen Brett R | Chief Accounting Officer | A | 60,800 | $0.00 | $0.00 |
| Dec 18, 2025 | AKKARAJU SRINIVAS | Director | BUY | 479,847 | $10.42 | $5.0M |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 5 neutral. Avg impact: 4.3/10.
NEUTRAL
8-K
4/10
Kalaris Therapeutics reported Q1 2026 financial results, with net loss widening to $10.9M from $10.2
May 12, 2026
NEUTRAL
PRESS-RELEASE
4/10
Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by
May 12, 2026
NEUTRAL
DEFA14A
3/10
Kalaris Therapeutics is holding its 2026 annual meeting to vote on the election of three Class III d
Apr 24, 2026
BEARISH
EFFECT
7/10
Kalaris Therapeutics has two S-3 shelf registrations that became effective on April 13, 2026. The fi
Apr 14, 2026
NEUTRAL
8-K
3/10
Kalaris Therapeutics CFO Matthew Gall resigned effective April 14, 2026, with Chief Accounting Offic
Apr 10, 2026
BEARISH
S-3
6/10
Kalaris Therapeutics has filed an S-3 shelf registration allowing it to raise up to $350 million thr
Apr 3, 2026
NEUTRAL
S-3
3/10
Kalaris Therapeutics filed an S-3 shelf registration to allow certain selling stockholders to resell
Apr 3, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 6 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$18.75 mean target
+359.0% upside
Strong Buy (3.00)
$7.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $4.09 |
| Target Low | $7.00 |
| Target Mean | $18.75 |
| Target Median | $19.50 |
| Target High | $25.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.50 | $-0.55 | $-0.38 | 17.8% | +8.8% | 1↑ 0↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.53 | $-0.58 | $-0.39 | 17.6% | +7.8% | 1↑ 0↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-2.05 | $-2.19 | $-1.62 | 28.0% | +9.0% | 1↑ 0↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$-1.58 | $-2.21 | $0.65 | 23.0% | -8.6% | 1↑ 0↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.501 | |
| 7d ago | $-0.542 | +0.040 |
| 30d ago | $-0.550 | +0.049 |
| 60d ago | $-0.640 | +0.139 |
| 90d ago | $-0.640 | +0.139 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Wedbush | INITIATE | — | Outperform |
| May 13, 2026 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Apr 16, 2026 | Morgan Stanley | INITIATE | — | Overweight |
| Dec 23, 2025 | Chardan Capital | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Apr 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% | |
| Jan 1, 2026 | 5 | 5 | 2 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
58°
Warm
Bearish
Neutral
Bullish
2 mentions
1 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 25, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 23, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 20, 2026
earnings_calendar
KLRS Q1 2026 Earnings Scheduled — 2026-05-20
May 12, 2026
earnings
Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="center"><em>Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be available to support up
May 12, 2026
earnings_calendar
KLRS Q1 2026 Earnings Scheduled — 2026-05-12
Mar 17, 2026
earnings
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><em>Positive initial data reported from Phase 1a Single Ascending Dose</em> <em>study in nAMD in December 2025; preliminary data fro
Mar 5, 2026
earnings_calendar
KLRS Q4 2025 Earnings After Market Close — 2026-03-05